跳至主要内容
临床试验/NCT04667182
NCT04667182撤回不适用

Meal-centric Insulin Dosing for Optimized Post-Prandial Glucose Control in People Using Multiple Daily Injections

Eli Lilly and Company2 个研究点 分布在 1 个国家开始时间: 2021年1月25日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Change from Baseline in Area Under the Curve (AUC) of CGM

研究概览

简要总结

The main purpose of this study is to determine whether combining meal, glucose and insulin data in a web-based system will improve management of type 1 (T1D) and type 2 diabetes (T2D). No study drug will be given. The study will last about 18 weeks.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
25 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individuals with type 1 or type 2 diabetes for >3 years by clinical diagnosis who use basal insulin, in addition to at least one injection of meal time insulin per day
  • Insulin pen use for at least 3 months
  • Current use of or willingness to use Dexcom G6 at least 6 out of 7 days per week
  • A1c 6.5-9.5%

排除标准

  • Currently using any form of insulin pump, including hybrid closed-loop system (e.g., Medtronic 670G)
  • Individuals requiring single insulin boluses of >40 units
  • Individuals planning to follow a specific diet plan for weight loss
  • Inability to consume regular, consistent meals
  • Individuals who have had severe hypoglycemia with seizure or coma within the past 6 months
  • Individuals who have been hospitalized for diabetic ketoacidosis (DKA) within the past 6 months

结局指标

主要结局

Change from Baseline in Area Under the Curve (AUC) of CGM

时间窗: Baseline, Week 17

Change from Baseline in AUC of CGM

次要结局

  • Percent Time-in-Range (TIR)(Baseline through Week 17)
  • Qualitative data from study investigators and participants(Baseline through Week 17)
  • Time Above Range (TAR)(Baseline through Week 17)
  • Postprandial TIR(Baseline through Week 17)
  • Time Below Range (TBR) <70 mg/dL(Baseline through Week 17)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

A Study of Glucose Control in Participants With Type... | 临床试验